HGS Cuts High Dose Albuferon In Phase III After Increased Pulmonary Events

Lower 900 mcg dose of albinterferon alfa-2b is on track for hepatitis C filing in fall 2009, Human Genome Sciences says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet